omeprazole has been researched along with Metaplasia in 35 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Metaplasia: A condition in which there is a change of one adult cell type to another similar adult cell type.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to assess whether adequate intra-esophageal acid suppression could be achieved with once daily versus twice daily omeprazole in patients with gastroesophageal specialized intestinal metaplasia (GEJSIM), short-segment (SSBE) and long-segment Barrett's esophagus (LSBE)." | 7.79 | The dose of omeprazole required to achieve adequate intraesophageal acid suppression in patients with gastroesophageal junction specialized intestinal metaplasia and Barrett's esophagus. ( Bassett, JT; Horwhat, JD; Maydonovitch, CL; Moawad, FJ; Veerappan, GR; Watson, JT; Wong, RK, 2013) |
| " pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole." | 7.71 | Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001) |
| " We have established a protocol for long-term administration of OPZ in rats that is a useful model for analyzing morphological changes after long-term PPI therapy." | 5.34 | Development of pancreatic acinar cell metaplasia after successful administration of omeprazole for 6 months in rats. ( Hagiwara, T; Hattori, T; Ling, ZQ; Mukaisho, K; Sugihara, H, 2007) |
| "In this double-blind study, patients with precancerous gastric dysplasia with or without intestinal metaplasia (IM) received either conventional treatment consisting of omeprazole and sucralfate (control group) or conventional treatment plus ATRA." | 5.20 | Addition of all-trans-retinoic acid to omeprazole and sucralfate therapy improves the prognosis of gastric dysplasia. ( Bai, Y; Chang, Y; Gao, Q; Jiang, Y; Jin, J; Jin, Z; Li, X; Lu, L; Su, X; Wu, L; Xing, L; Zhao, X; Zheng, Y, 2015) |
| "Two hundred and forty-three patients received rabeprazole (20 mg or 10 mg) or omeprazole (20 mg) once daily for up to 5 years, for gastro-oesophageal reflux disease and 51% completed the whole 5 year period." | 5.11 | Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. ( Fiocca, R; Jacobs, A; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2005) |
| " pylori-positive patients who had peptic ulcers or reflux oesophagitis were treated for 3 years with either omeprazole (20 mg/day) alone (n=7) or with omeprazole for primary therapy (8 weeks), followed by famotidine (40 mg/day) for maintenance therapy (n=134)." | 5.09 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. ( Mashiba, H; Matsumura, N; Okamoto, S; Sasaki, N; Taniyama, K; Uemura, N; Yamaguchi, S; Yamamoto, S, 2000) |
| "The purpose of this study was to assess whether adequate intra-esophageal acid suppression could be achieved with once daily versus twice daily omeprazole in patients with gastroesophageal specialized intestinal metaplasia (GEJSIM), short-segment (SSBE) and long-segment Barrett's esophagus (LSBE)." | 3.79 | The dose of omeprazole required to achieve adequate intraesophageal acid suppression in patients with gastroesophageal junction specialized intestinal metaplasia and Barrett's esophagus. ( Bassett, JT; Horwhat, JD; Maydonovitch, CL; Moawad, FJ; Veerappan, GR; Watson, JT; Wong, RK, 2013) |
| " pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole." | 3.71 | Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001) |
| " Seventeen patients with apparently complete endoscopic and histological eradication of Barrett's oesophagus were re-evaluated at one year; eight (47%) disclosed relapsing islands of Barrett metaplasia despite continuous omeprazole therapy (10-40 mg/day)." | 3.70 | Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. ( Cremer, M; Delhaye, M; Devière, J; Peny, MO; Van Laethem, JL, 1998) |
| "KTP laser destruction of Barrett's esophagus induced mucosal regeneration with normal squamous cell epithelium in combination with acid suppression." | 2.69 | KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. ( Ell, C; Gossner, L; Hahn, EG; May, A; Seitz, G; Stolte, M, 1999) |
| "Gastroesophageal reflux is a well-recognized complication of obesity." | 1.35 | Case reports--resolution of Barrett's disease and esophageal epithelial atypia after gastric bypass and LAP-BAND. ( Chang, CG; Perez, E, 2009) |
| " We have established a protocol for long-term administration of OPZ in rats that is a useful model for analyzing morphological changes after long-term PPI therapy." | 1.34 | Development of pancreatic acinar cell metaplasia after successful administration of omeprazole for 6 months in rats. ( Hagiwara, T; Hattori, T; Ling, ZQ; Mukaisho, K; Sugihara, H, 2007) |
| "Chronic gastritis was evaluated according to sydney system." | 1.33 | [Prospective study of 420 biopsies realised in patients with duodenal ulcer with positive Helicobacter pylori]. ( Ben Ayed, M; Ben Khelifa, H; Chedly-Debbiche, A; Gargouri, D; Ghorbel, AJ; Kharrat, J; Khayat, O; Kilani, A; Souissi, A; Zeddini, A, 2006) |
| "Gastric metaplasia was endoscopically and histologically evaluated before and after eradication of this bacterium." | 1.32 | Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori. ( Sano, T; Urakami, Y, 2003) |
| "Gastroesophageal reflux disease has a multifactorial etiology." | 1.31 | Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease. ( Gadenstaetter, M; Klaus, A; Klingler, PJ; Obrist, P; Profanter, C; Weiss, H; Wetscher, GJ; Wykypiel, H, 2001) |
| "Endoscopic reversal of Barrett's esophagus with multipolar electrocoagulation and high-dose omeprazole has been previously described but long-term results are not available." | 1.30 | Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus. ( Bhattacharyya, A; Garewal, HS; Sampliner, RE; Sharma, P, 1999) |
| "In this case report, a patient with Barrett's esophagus of stable length had half the circumference of the Barrett's epithelium ablated with laser therapy while on a high-dose proton-pump inhibitor." | 1.29 | Regression of Barrett's esophagus by laser ablation in an anacid environment. ( Fennerty, MB; Garewal, HS; Hixson, LJ; Sampliner, RE, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (34.29) | 18.2507 |
| 2000's | 19 (54.29) | 29.6817 |
| 2010's | 3 (8.57) | 24.3611 |
| 2020's | 1 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Kodama, M | 1 |
| Okimoto, T | 1 |
| Mizukami, K | 1 |
| Hirashita, Y | 1 |
| Wada, Y | 1 |
| Fukuda, M | 1 |
| Matsunari, O | 1 |
| Okamoto, K | 1 |
| Ogawa, R | 1 |
| Fukuda, K | 1 |
| Kudo, Y | 1 |
| Kawahara, Y | 1 |
| Murakami, K | 1 |
| Watson, JT | 1 |
| Moawad, FJ | 1 |
| Veerappan, GR | 1 |
| Bassett, JT | 1 |
| Maydonovitch, CL | 1 |
| Horwhat, JD | 1 |
| Wong, RK | 1 |
| Jin, J | 1 |
| Li, X | 1 |
| Xing, L | 1 |
| Chang, Y | 1 |
| Wu, L | 1 |
| Jin, Z | 1 |
| Su, X | 1 |
| Bai, Y | 1 |
| Zheng, Y | 1 |
| Jiang, Y | 1 |
| Zhao, X | 1 |
| Lu, L | 1 |
| Gao, Q | 1 |
| Koak, Y | 1 |
| Davies, SE | 1 |
| Winslet, M | 1 |
| Chang, CG | 1 |
| Perez, E | 1 |
| Ji, R | 1 |
| Zuo, XL | 1 |
| Yu, T | 1 |
| Gu, XM | 1 |
| Li, Z | 1 |
| Zhou, CJ | 1 |
| Li, YQ | 1 |
| Urakami, Y | 2 |
| Sano, T | 1 |
| Overholt, BF | 2 |
| Panjehpour, M | 2 |
| Halberg, DL | 1 |
| Leung, WK | 2 |
| Lin, SR | 2 |
| Ching, JY | 2 |
| To, KF | 2 |
| Ng, EK | 2 |
| Chan, FK | 1 |
| Lau, JY | 2 |
| Sung, JJ | 2 |
| Marusic, M | 1 |
| Babic, Z | 1 |
| Nesanovic, M | 1 |
| Lucijanic-Mlinac, M | 1 |
| Stajcar, V | 1 |
| Rindi, G | 1 |
| Fiocca, R | 2 |
| Morocutti, A | 1 |
| Jacobs, A | 1 |
| Miller, N | 1 |
| Thjodleifsson, B | 1 |
| Salih, BA | 1 |
| Abasiyanik, MF | 1 |
| Saribasak, H | 1 |
| Huten, O | 1 |
| Sander, E | 1 |
| Chan, AO | 1 |
| Peng, JZ | 1 |
| Lam, SK | 1 |
| Lai, KC | 1 |
| Yuen, MF | 1 |
| Cheung, HK | 1 |
| Kwong, YL | 1 |
| Rashid, A | 1 |
| Chan, CK | 1 |
| Wong, BC | 1 |
| Khayat, O | 1 |
| Kilani, A | 1 |
| Chedly-Debbiche, A | 1 |
| Zeddini, A | 1 |
| Gargouri, D | 1 |
| Kharrat, J | 1 |
| Souissi, A | 1 |
| Ghorbel, AJ | 1 |
| Ben Ayed, M | 1 |
| Ben Khelifa, H | 1 |
| Hagiwara, T | 1 |
| Mukaisho, K | 1 |
| Ling, ZQ | 1 |
| Sugihara, H | 1 |
| Hattori, T | 1 |
| Li, XB | 1 |
| Ge, ZZ | 1 |
| Chen, XY | 1 |
| Liu, WZ | 1 |
| Solcia, E | 1 |
| Villani, L | 1 |
| Luinetti, O | 1 |
| Boldorini, R | 1 |
| Trespi, E | 1 |
| Perego, M | 1 |
| Alvisi, C | 1 |
| Lazzaroni, M | 1 |
| Bianchi Porro, G | 1 |
| Sampliner, RE | 2 |
| Hixson, LJ | 1 |
| Fennerty, MB | 1 |
| Garewal, HS | 2 |
| Khulusi, S | 1 |
| Badve, S | 1 |
| Patel, P | 1 |
| Lloyd, R | 1 |
| Marrero, JM | 1 |
| Finlayson, C | 1 |
| Mendall, MA | 1 |
| Northfield, TC | 1 |
| Kimura, M | 1 |
| Seki, H | 1 |
| Rudnicka, L | 1 |
| Bobrzyński, A | 1 |
| Stachura, J | 1 |
| Katsoulis, S | 1 |
| Fölsch, UR | 1 |
| Van Laethem, JL | 1 |
| Cremer, M | 1 |
| Peny, MO | 1 |
| Delhaye, M | 1 |
| Devière, J | 1 |
| Gossner, L | 1 |
| May, A | 1 |
| Stolte, M | 1 |
| Seitz, G | 1 |
| Hahn, EG | 1 |
| Ell, C | 1 |
| Haydek, JM | 1 |
| Sharma, P | 1 |
| Bhattacharyya, A | 1 |
| Declich, P | 1 |
| Ambrosiani, L | 1 |
| Prada, A | 1 |
| Bortoli, A | 1 |
| Bellone, S | 1 |
| Tavani, E | 1 |
| Gozzini, C | 1 |
| Kochman, ML | 1 |
| Zhou, LY | 1 |
| Wang, RT | 1 |
| Lee, YT | 1 |
| Yeung, CK | 1 |
| Chao, W | 1 |
| Chung, SC | 1 |
| Sauer, J | 1 |
| Junginger, T | 1 |
| Uemura, N | 1 |
| Okamoto, S | 1 |
| Yamamoto, S | 1 |
| Matsumura, N | 1 |
| Yamaguchi, S | 1 |
| Mashiba, H | 1 |
| Sasaki, N | 1 |
| Taniyama, K | 1 |
| Hirschowitz, BI | 1 |
| Haber, MM | 1 |
| Ohkusa, T | 1 |
| Fujiki, K | 1 |
| Takashimizu, I | 1 |
| Kumagai, J | 1 |
| Tanizawa, T | 1 |
| Eishi, Y | 1 |
| Yokoyama, T | 1 |
| Watanabe, M | 1 |
| Wetscher, GJ | 1 |
| Gadenstaetter, M | 1 |
| Klingler, PJ | 1 |
| Weiss, H | 1 |
| Obrist, P | 1 |
| Wykypiel, H | 1 |
| Klaus, A | 1 |
| Profanter, C | 1 |
| Ciancio, G | 1 |
| Nuti, M | 1 |
| Orsini, B | 1 |
| Iovi, F | 1 |
| Ortolani, M | 1 |
| Palomba, A | 1 |
| Amorosi, A | 1 |
| Surrenti, E | 1 |
| Ilani, SM | 1 |
| Surrenti, C | 1 |
1 review available for omeprazole and Metaplasia
| Article | Year |
|---|---|
[Conservative and surgical antireflux therapy as prevention of carcinoma].
Topics: Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Biopsy; Clinical Trials as Topic; Esophageal N | 2000 |
11 trials available for omeprazole and Metaplasia
| Article | Year |
|---|---|
Addition of all-trans-retinoic acid to omeprazole and sucralfate therapy improves the prognosis of gastric dysplasia.
Topics: Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Mucosa; Humans; Intesti | 2015 |
Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Disease Progression; Drug Therapy, Combination | 2004 |
Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2005 |
Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Dis | 2005 |
A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2005 |
Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Cadherins; Chronic Disease; Clarithromycin; D | 2006 |
Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients.
Topics: Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Gastrit | 1994 |
Pathogenesis of gastric metaplasia of the human duodenum: role of Helicobacter pylori, gastric acid, and ulceration.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Du | 1996 |
KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophagus; Esophageal Neo | 1999 |
Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Endoscopy; Female; Gastric | 2000 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan.
Topics: Anti-Ulcer Agents; Enzyme Inhibitors; Famotidine; Gastric Mucosa; Gastritis; Gastroscopy; Helicobact | 2000 |
23 other studies available for omeprazole and Metaplasia
| Article | Year |
|---|---|
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Female; Follow-Up Studies; | 2021 |
The dose of omeprazole required to achieve adequate intraesophageal acid suppression in patients with gastroesophageal junction specialized intestinal metaplasia and Barrett's esophagus.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Dose-Response Relationship, Drug; Esophagogastric Junction; Ga | 2013 |
Effect of Roux-en-Y surgery and medical intervention on Barrett's-type changes: an in vivo model.
Topics: Anastomosis, Roux-en-Y; Animals; Barrett Esophagus; Disease Models, Animal; Gastroesophageal Reflux; | 2008 |
Case reports--resolution of Barrett's disease and esophageal epithelial atypia after gastric bypass and LAP-BAND.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Esophagitis; Esophagoscopy; Gastrectomy; Gastric Bypass; Gastr | 2009 |
Mucosal barrier defects in gastric intestinal metaplasia: in vivo evaluation by confocal endomicroscopy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Chi-Square Distribution; | 2012 |
Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Cicatrix; Convalescence; Drug The | 2003 |
Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophagus; Esophageal Neo | 2003 |
[Prospective study of 420 biopsies realised in patients with duodenal ulcer with positive Helicobacter pylori].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; D | 2006 |
Development of pancreatic acinar cell metaplasia after successful administration of omeprazole for 6 months in rats.
Topics: alpha-Amylases; Animals; Anti-Ulcer Agents; Body Weight; Chromogranin A; Dose-Response Relationship, | 2007 |
Duodenal gastric metaplasia and Helicobacter pylori infection in patients with diffuse nodular duodenitis.
Topics: Adult; Aged; Case-Control Studies; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Duode | 2007 |
Regression of Barrett's esophagus by laser ablation in an anacid environment.
Topics: Aged; Barrett Esophagus; Biopsy; Combined Modality Therapy; Esophagoscopy; Esophagus; Humans; Laser | 1993 |
Gastric metaplasia and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer | 1997 |
Short-term eradication therapy for Helicobacter pylori does not reduce the incidence of gastric metaplasia in duodenal ulcer patients.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Heli | 1997 |
[Is long-term acid suppression dangerous in existing Helicobacter pylori infection?].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Fundopli | 1997 |
Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results.
Topics: Adult; Antacids; Anti-Ulcer Agents; Argon; Barrett Esophagus; Combined Modality Therapy; Electrocoag | 1998 |
Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antineoplastic Agents; Barrett Es | 1999 |
Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus.
Topics: Aged; Anti-Ulcer Agents; Barrett Esophagus; Biopsy; Combined Modality Therapy; Electrocoagulation; E | 1999 |
Fundic metaplasia with parietal cell hyperplasia of the antrum: a lesion possibly associated with long term use of omeprazole.
Topics: Anti-Ulcer Agents; Biopsy; Gastric Fundus; Humans; Hyperplasia; Long-Term Care; Male; Metaplasia; Mi | 1999 |
Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Combined Modality Therapy; Endoscopy; Esophagus; Follow-Up Stu | 1999 |
Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Enterochromaffin-like Cells; Enzyme Inhibitors; Fema | 2001 |
Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 2001 |
Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Benzimid | 2001 |
Regression of duodenal gastric metaplasia in Helicobacter pylori positive patients with duodenal ulcer disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; | 2002 |